XML 48 R37.htm IDEA: XBRL DOCUMENT
v3.25.2

Collaboration and license agreements - Narrative (Details) $ / shares in Units, $ in Thousands |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2025 USD ($) target performanceObligation | Mar. 01, 2024 USD ($) target | Dec. 11, 2023 USD ($) target performanceObligation | May 29, 2023 USD ($) $ / shares shares | Apr. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) developmentCandidate | Apr. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) target | Nov. 30, 2020 USD ($) target | Feb. 29, 2020 USD ($) protein | Dec. 31, 2018 USD ($) target performanceObligation | Jun. 30, 2025 USD ($) target performanceObligation | Jun. 30, 2024 USD ($) | Jun. 30, 2025 USD ($) target performanceObligation | Jun. 30, 2024 USD ($) | Mar. 31, 2025 USD ($) | Dec. 31, 2024 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations | performanceObligation |  |  |  |  |  |  |  |  |  |  |  | 12 |  |  |  |  |  |
Transaction price allocated to performance obligation | $ 23,064 |  |  |  |  |  |  |  |  |  |  |  | $ 23,064 |  | $ 23,064 |  |  |
Contract with customer, liability | 43,770 |  |  |  |  |  |  |  |  |  |  |  | 43,770 |  | 43,770 |  |  | $ 47,169
Revenue from collaboration agreements |  |  |  |  |  |  |  |  |  |  |  |  | 6,463 | $ 12,006 | 13,701 | $ 15,045 |  |
Revenue recognized that was included in the contract liability at the beginning of the period |  |  |  |  |  |  |  |  |  |  |  |  | 6,512 | 2,065 | 11,821 | 5,003 |  |
Discovery, Regulatory, and Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount eligible to receive | $ 740,000 |  |  |  |  |  |  |  |  |  |  |  | $ 740,000 |  | $ 740,000 |  |  |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for termination of agreement |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
MKDG Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of potential research and development targets | target | 2 | 2 |  |  |  |  |  |  |  |  |  |  | 2 |  | 2 |  |  |
Upfront payment |  | $ 16,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone achieved |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Addition to the transaction price | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |  | $ 1,000 |  |  |
Number of performance obligations | performanceObligation | 2 |  |  |  |  |  |  |  |  |  |  |  | 2 |  | 2 |  |  |
Transaction price allocated to performance obligation | $ 17,000 |  |  |  |  |  |  |  |  |  |  |  | $ 17,000 |  | $ 17,000 |  |  |
Contract with customer, liability | 11,892 |  |  |  |  |  |  |  |  |  |  |  | 11,892 |  | 11,892 |  |  | 13,373
Revenue from collaboration agreements |  |  |  |  |  |  |  |  |  |  |  |  | 3,428 | 1,894 | 6,581 | 1,949 |  |
MKDG Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for termination of agreement |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations | performanceObligation |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract with customer, liability | 3,843 |  |  |  |  |  |  |  |  |  |  |  | 3,843 |  | 3,843 |  |  | 6,022
Option to include number of additional targets | target |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from collaboration |  |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated transaction price | 10,000 |  |  |  |  |  |  |  |  |  |  |  | 10,000 |  | 10,000 |  |  |
Revenue from collaboration agreements |  |  |  |  |  |  |  |  |  |  |  |  | 1,049 | 1,102 | 2,178 | 1,747 |  |
Merck Agreement | Research and development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount eligible to receive |  |  | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for termination of agreement |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Betta Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | 10,000 |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone achieved |  |  |  |  |  |  |  |  | $ 2,000 |  |  |  |  |  |  |  |  |
Contract with customer, liability | 14,970 |  |  |  |  |  |  |  |  |  |  |  | 14,970 |  | 14,970 |  |  | $ 15,281
Estimated transaction price | 135,000 |  |  |  |  |  |  |  |  |  |  |  | 135,000 |  | 135,000 |  |  |
Stock repurchase program, number of shares authorized to be repurchased (in shares) | shares |  |  |  | 5,567,928 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock repurchase program, authorized amount |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price (in dollars per share) | $ / shares |  |  |  | $ 4.49 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock repurchase program, premium percentage |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Duration of trading day volume weighted average closing price |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trading days prior to the effective date of the Stock Purchase Agreement |  |  |  | 2 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price from closing of the stock purchase agreement | 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected consideration to be received from manufactured clinical supply | 118,000 |  |  |  |  |  |  |  |  |  |  |  | 118,000 |  | 118,000 |  |  |
Revenue from collaboration agreements |  |  |  |  |  |  |  |  |  |  |  |  | 54 | $ 0 | 514 | $ 0 |  |
Betta Agreements | Research and development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount eligible to receive |  |  |  | $ 357,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Betta Agreements | Drug Application Approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount eligible to receive |  |  |  | $ 40,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restated Roche Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone achieved |  |  |  |  |  |  |  | $ 2,000 |  |  |  |  |  |  |  |  |  |
Addition to the transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000 |
Number of targets | target |  |  |  |  |  |  |  |  | 2 | 2 |  |  |  |  |  |  |  |
Additional upfront consideration received |  |  |  |  |  |  |  |  |  |  |  | $ 40,000 |  |  |  |  |  |
Number of potential targets | target |  |  |  |  |  |  |  |  |  | 5 |  | 6 |  |  |  |  |  |
Annual research plan payments receivables |  |  |  |  |  |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |
Option exercise fees |  |  |  |  |  |  |  |  |  | $ 8,000 |  |  |  |  |  |  |  |
Restated Roche Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for termination of agreement |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |
Restated Roche Agreement | Maximum | Research, development and commercial milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount eligible to receive |  |  |  |  |  |  |  |  |  | $ 273,000 |  |  |  |  |  |  |  |
Restated Roche Agreement | Maximum | One-time sales-based payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount eligible to receive |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |
Restated Roche Agreement | Lead series identification achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fees |  |  |  |  |  |  |  |  |  | $ 2,000 |  |  |  |  |  |  |  |
Biogen Research and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement, period |  |  |  |  |  |  |  |  |  |  | 54 months |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  |  | $ 45,000 |  |  |  |  |  |  |
Revenue recognized that was included in the contract liability at the beginning of the period |  |  |  |  |  | $ 8,000 | $ 8,000 |  |  |  |  |  |  |  |  |  |  |
Number of development candidates | developmentCandidate |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |
Biogen Research and License Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of targeted protein degradation | protein |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |
Biogen Research and License Agreement | Maximum | Research and development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment received |  |  |  |  |  |  |  |  |  |  | $ 35,000 |  |  |  |  |  |  |
Biogen Research and License Agreement | Maximum | One-time sales-based payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment received |  |  |  |  |  |  |  |  |  |  | $ 26,000 |  |  |  |  |  |  |
Restated Roche Agreement And Biogen License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price allocated to performance obligation | $ 161,400 |  |  |  |  |  |  |  |  |  |  |  | $ 161,400 |  | $ 161,400 |  |  |

X
- Definition Additional upfront consideration. + References No definition available. + Details
Name: | cccc_AdditionalUpfrontConsideration
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual research plan payments receivables. + References No definition available. + Details
Name: | cccc_AnnualResearchPlanPaymentsReceivables
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Addition To The Transaction Price + References No definition available. + Details
Name: | cccc_CollaborativeArrangementAdditionToTheTransactionPrice
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Estimated Transaction Price + References No definition available. + Details
Name: | cccc_CollaborativeArrangementEstimatedTransactionPrice
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Potential Proceeds From Collaboration + References No definition available. + Details
Name: | cccc_CollaborativeArrangementPotentialProceedsFromCollaboration
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Regulatory Milestone Achieved + References No definition available. + Details
Name: | cccc_CollaborativeArrangementRegulatoryMilestoneAchieved
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expected Consideration To Be Received From Manufactured Clinical Supply + References No definition available. + Details
Name: | cccc_ExpectedConsiderationToBeReceivedFromManufacturedClinicalSupply
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Non refundable upfront payment. + References No definition available. + Details
Name: | cccc_NonRefundableUpfrontPayment
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Notice period for termination of agreement. + References No definition available. + Details
Name: | cccc_NoticePeriodForTerminationOfAgreement
Namespace Prefix: | cccc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Development Candidates + References No definition available. + Details
Name: | cccc_NumberOfDevelopmentCandidates
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Performance Obligations + References No definition available. + Details
Name: | cccc_NumberOfPerformanceObligations
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Potential Research and Development Targets + References No definition available. + Details
Name: | cccc_NumberOfPotentialResearchAndDevelopmentTargets
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of potential targets. + References No definition available. + Details
Name: | cccc_NumberOfPotentialTargets
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of targeted protein degradation. + References No definition available. + Details
Name: | cccc_NumberOfTargetedProteinDegradation
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of targets. + References No definition available. + Details
Name: | cccc_NumberOfTargets
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Option exercise fee. + References No definition available. + Details
Name: | cccc_OptionExerciseFee
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option To Include Number of Additional Targets + References No definition available. + Details
Name: | cccc_OptionToIncludeNumberOfAdditionalTargets
Namespace Prefix: | cccc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research and development agreement period. + References No definition available. + Details
Name: | cccc_ResearchAndDevelopmentAgreementPeriod
Namespace Prefix: | cccc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock Repurchase Program, Duration of Trading Day Volume Weighted Average Closing Price + References No definition available. + Details
Name: | cccc_StockRepurchaseProgramDurationOfTradingDayVolumeWeightedAverageClosingPrice
Namespace Prefix: | cccc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock Repurchase Program, Premium Percentage + References No definition available. + Details
Name: | cccc_StockRepurchaseProgramPremiumPercentage
Namespace Prefix: | cccc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Stock Repurchase Program, Trading Days Prior To The Effective Date Of The Stock Purchase Agreement + References No definition available. + Details
Name: | cccc_StockRepurchaseProgramTradingDaysPriorToTheEffectiveDateOfTheStockPurchaseAgreement
Namespace Prefix: | cccc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Transaction price allocated to performance obligation. + References No definition available. + Details
Name: | cccc_TransactionPriceAllocatedToPerformanceObligation
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Transaction Price From Closing of the Stock Purchase Agreement + References No definition available. + Details
Name: | cccc_TransactionPriceFromClosingOfTheStockPurchaseAgreement
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront fees. + References No definition available. + Details
Name: | cccc_UpfrontFees
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | cccc_UpfrontPayment
Namespace Prefix: | cccc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details
Name: | srt_StockRepurchaseProgramAuthorizedAmount1
Namespace Prefix: | srt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details
Name: | srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
Namespace Prefix: | srt_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of billed or unbilled claims or other similar items subject to uncertainty concerning their determination or ultimate realization under long-term contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_ContractsReceivableClaimsAndUncertainAmounts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_DiscoveryRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cccc_MKDGAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cccc_MerckAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchAndDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cccc_BettaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_DrugApplicationApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cccc_RestatedRocheAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OneTimeSalesBasedPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cccc_LeadSeriesIdentificationAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cccc_BiogenResearchAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cccc_RestatedRocheAgreementAndBiogenLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |